Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
整合基因组学方法发现，SCRN1 的上调是携带致癌 EGFR 突变的 PC9 细胞获得厄洛替尼耐药性的一种新机制
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.7318
Kim Nayoung, Cho Ahye, Watanabe Hideo, Choi Yoon-La, Aziz Meraj, Kassner Michelle, Joung Je-Gun, Park Angela Kyung-Joo, Francis Joshua M, Bae Joon Seol, Ahn Soo-Min, Kim Kyoung-Mee, Park Joon Oh, Park Woong-Yang, Ahn Myung-Ju, Park Keunchil, Koo Jaehyung, Yin Hongwei Holly, Cho Jeonghee
